Dare Bioscience Inc
$ 1.40
5.26%
07 Aug - close price
- Market Cap 20,971,300 USD
- Current Price $ 1.40
- High / Low $ 1.42 / 1.36
- Stock P/E N/A
- Book Value 0.05
- EPS -0.91
- Next Earning Report 2026-08-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.32 %
- ROE -25.43 %
- 52 Week High 3.78
- 52 Week Low 1.13
About
Dar Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing women's health products in the United States. The company is headquartered in San Diego, California.
Analyst Target Price
$9.67
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-14 | 2026-03-26 | 2025-11-13 | 2025-08-14 | 2025-05-13 | 2025-03-31 | 2024-11-14 | 2024-08-12 | 2024-05-14 | 2024-03-28 | 2023-11-09 | 2023-08-10 |
| Reported EPS | -0.2 | -0.1006 | -0.28 | -0.45 | -0.5 | -0.65 | -0.55 | -0.89 | -0.84 | -0.06 | -1.08 | -1.2 |
| Estimated EPS | -0.3 | -0.42 | -0.4 | -0.58 | -0.58 | -0.6333 | -0.71 | -0.66 | -0.72 | -0.1 | -1.2 | -1.08 |
| Surprise | 0.1 | 0.3194 | 0.12 | 0.13 | 0.08 | -0.0167 | 0.16 | -0.23 | -0.12 | 0.04 | 0.12 | -0.12 |
| Surprise Percentage | 33.3333% | 76.0476% | 30% | 22.4138% | 13.7931% | -2.637% | 22.5352% | -34.8485% | -16.6667% | 40% | 10% | -11.1111% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-13 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.33 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: DARE
2026-08-08 15:09:22
Dare Bioscience Inc (DARE) has an earnings forecast score of 8.00, ranking 58th in the Pharmaceuticals industry, with a consensus analyst price target of $11.50, suggesting a significant upside. Three analysts have rated the stock as a "Buy" with a target price increase of +626.82%. The company's previous quarter's EPS was -$0.10, outperforming the market expectation of -$0.21, and the next quarter's EPS is expected to be -$0.24.
2026-08-08 04:40:23
Dare Bioscience (DARE.US) is scheduled to release its earnings report on August 13, after the market closes. This announcement provides key information for investors and stakeholders anticipating the company's financial performance.
2026-08-07 09:39:45
This article provides a technical analysis of Dare Bioscience Inc (DARE), focusing on its support, resistance, and various technical indicators and moving averages. As of the analysis, DARE's stock price momentum score is 6.20, trading between a resistance level of $1.94 and a support level of $0.93. The analysis presents a mix of buy, sell
2026-08-07 04:40:23
Daré Bioscience, Inc. (NASDAQ: DARE) announced it will host a conference call and webcast on Thursday, August 13, 2026, at 4:30 PM Eastern Time. The purpose of the call is to review its financial results for the second quarter ended June 30, 2026, and provide a company update. Interested parties can access the call via phone or live webcast, with an archived replay available for 90 days.
2026-08-06 15:27:00
Daré Bioscience, Inc. (NASDAQ: DARE) will host a conference call and webcast on Thursday, August 13, 2026, at 4:30 PM Eastern Time to discuss its financial results for the second quarter ended June 30, 2026, and provide a company update. Investors can access the call via phone or live webcast, which will also be archived for replay. Daré Bioscience is a health biotech company focused on women's health solutions across various areas.
2026-08-06 14:39:45
This article provides detailed financial information for Daré Bioscience, Inc. (DARE), including its current stock price, historical data, analyst ratings, and company overview. It highlights the company's focus on developing therapies for women's health and outlines its various product candidates in different stages of development. The report also includes performance metrics such as trailing total returns and earnings trends.
